Principal Financial Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-22,706
| Closed | -$344K | – | 2596 |
|
|
2022
Q3 | $344K | Sell |
22,706
-18,321
| -45% | -$213K | ﹤0.01% | 2044 |
|
|
2022
Q2 | $307K | Buy |
+41,027
| New | +$289K | ﹤0.01% | 2170 |
|
|
2021
Q3 | – | Sell |
-418,624
| Closed | -$6.7M | – | 2640 |
|
|
2021
Q2 | $6.7M | Sell |
418,624
-110,742
| -21% | -$1.9M | ﹤0.01% | 1618 |
|
|
2021
Q1 | $9.46M | Buy |
+529,366
| New | +$9.14M | 0.01% | 1415 |
|
|
2019
Q3 | – | Sell |
-6,983
| Closed | -$206K | – | 2274 |
|
|
2019
Q2 | $206K | Buy |
6,983
+105
| +2% | +$4.05K | ﹤0.01% | 2140 |
|
|
2019
Q1 | $327K | Sell |
6,878
-8,588
| -56% | -$378K | ﹤0.01% | 2020 |
|
|
2018
Q4 | $558K | Sell |
15,466
-3,474
| -18% | -$163K | ﹤0.01% | 1891 |
|
|
2018
Q3 | $1.17M | Buy |
18,940
+1,430
| +8% | +$91.9K | ﹤0.01% | 1825 |
|
|
2018
Q2 | $1.18M | Buy |
17,510
+5,285
| +43% | +$296K | ﹤0.01% | 1821 |
|
|
2018
Q1 | $663K | Sell |
12,225
-3,181
| -21% | -$178K | ﹤0.01% | 1896 |
|
|
2017
Q4 | $920K | Buy |
15,406
+9,763
| +173% | +$592K | ﹤0.01% | 1857 |
|
|
2017
Q3 | $274K | Sell |
5,643
-2,481
| -31% | -$135K | ﹤0.01% | 2041 |
|
|
2017
Q2 | $427K | Buy |
+8,124
| New | +$378K | ﹤0.01% | 1979 |
|
Principal Financial Group's AERI Position: Q4 2022 in Review
Principal Financial Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 22,706 shares — an estimated $344K sold.
Principal Financial Group first reported a position in AERI in Q2 2017 and held it in 13 quarters. The position peaked at $9.46M in Q1 2021. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Principal Financial Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Principal Financial Group sold 22,706 Aerie Pharmaceuticals shares in Q4 2022, an estimated $344K.
- Principal Financial Group first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 13 quarters.
- Principal Financial Group's Aerie Pharmaceuticals position peaked at $9.46M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Principal Financial Group's 13F filing for Q4 2022, filed 9 Feb 2023.